Medical Device Data Systems (MDDS) are typically Class I and exempt from premarket submission. Software as a Medical Device (SaMD) can range from Class I to Class III, with most products requiring a 510(k), De Novo, or PMA pathway. The two classifications have different risk profiles, different regulatory burdens, and very different software development implications. This guide covers the differences in detail, with a side-by-side cheat sheet at the end.
What are Medical Device Data Systems?
Medical Device Data Systems (MDDS) are software systems designed to collect, transfer, store, or display medical device data without altering its content or intended use.
These systems play a supportive role in healthcare by ensuring that data from medical devices is reliably managed and accessible to healthcare providers or other systems. Unlike software that directly influences clinical decisions, MDDS do not analyze or interpret data, making them a lower-risk category of medical device software.
One key distinction of MDDS is its passive functionality. They serve as intermediaries for data handling. Their focus is on reliability, interoperability, and secure data management rather than engaging in diagnosis, treatment, or monitoring. Regulatory requirements for MDDS reflect their low-risk nature.
Examples of MDDS include software that aggregates data from multiple wearable devices for display on a centralized dashboard, cloud systems that store patient monitoring data, or platforms that facilitate data transfer between a medical device and an electronic health record system.
What is Software as a Medical Device?
Software as a Medical Device (SaMD) refers to software intended to perform medical functions on its own, independent of the hardware of a physical medical device.
This includes applications for diagnosis, treatment, monitoring, or disease prevention, often leveraging advanced technologies such as artificial intelligence and machine learning. SaMD actively influences clinical decision-making, making its accuracy, safety, and performance critical to patient outcomes.
The key distinction between SaMD and MDDS is SaMD’s active role in healthcare: unlike MDDS, which passively handles data, SaMD processes and analyzes information to provide actionable insights. This functionality makes SaMD inherently higher risk and subject to more stringent regulatory oversight.
Examples of SaMD include AI-driven software that analyzes imaging data for early cancer detection, an app that predicts glucose levels based on data from a wearable biosensor, or telehealth platforms that assess patient symptoms to recommend treatment options.
Key Differences Between MDDS and SaMD
The main differences between these two types of medical software revolve around their functionality and purpose, risks, regulatory requirements, and subsequent development considerations.
Functionality and Purpose
The primary difference between MDDS and SaMD lies in their functionality and purpose.
MDDS are designed for the passive handling of medical data—they collect, store, transfer, or display information generated by medical devices without modifying or analyzing it. In contrast, SaMD takes an active role in medical care, performing functions such as diagnosing, monitoring, or treating conditions.
In short, MDDS facilitates efficient data management by serving as an intermediary between medical devices and users, while SaMD directly contributes to clinical outcomes through its processing and analytical capabilities. As a result, SaMD involves greater functional complexity and regulatory scrutiny compared to the lower-risk, utility-focused MDDS.
Risk and Impact
As mentioned above, MDDS carry a lower level of risk compared to SaMD because they do not directly affect clinical outcomes.
The risks associated with MDDS are typically related to data integrity, interoperability, and cybersecurity, rather than patient safety. In contrast, SaMD involves significantly higher risks because it directly impacts clinical decision-making and patient care. By analyzing and interpreting data, SaMD provides actionable medical insights, meaning that any error or failure in the software could lead to incorrect diagnoses, ineffective treatments, or patient harm.
Regulatory Classification
Due to substantial differences in risk between MDDS and SaMD, the regulatory compliance requirements for these systems differ.
MDDS, classified as low-risk devices, are typically categorized as Class I by the FDA and are often exempt from premarket submission requirements. Compliance for MDDS primarily involves meeting basic safety, security, and performance standards, with a focus on ensuring data integrity and protecting against breaches.
On the other hand, SaMD faces much stricter regulatory scrutiny due to its direct influence on patient care and outcomes. SaMD can be classified from Class I to Class III, depending on its intended use and potential risk to patients. Higher classifications require extensive premarket submissions, such as 510(k) clearance or premarket approval. SaMD development must adhere to international standards and processes, including IEC 62304 for software lifecycle processes and ISO 14971 for risk management. This adherence ensures thorough validation, clinical evidence, and ongoing post-market surveillance to maintain compliance and patient safety.
Development Considerations
The development considerations for these two types of software differ due to their distinct roles and regulatory demands.
MDDS development focuses on ensuring reliable data handling and interoperability. These systems are typically less complex, requiring straightforward design processes that emphasize data integrity, system reliability, and adherence to basic privacy regulations like HIPAA and GDPR.
The development of SaMD is significantly more complex, involving advanced features such as real-time data analysis, decision-support algorithms, and machine learning models. SaMD developers must also generate clinical evidence to validate their software’s performance and safety, often requiring substantial resources for testing and regulatory documentation. The complexity and active role of SaMD in patient care demand meticulous planning, extensive customization, and ongoing updates to maintain compliance and ensure patient safety.
| Characteristic | MDDS | SaMD |
|---|---|---|
| Collects, stores, transfers, or displays data | Yes | — |
| Analyzes, interprets, or processes data to make clinical decisions | — | Yes |
| Directly influences diagnosis, treatment, or monitoring | — | Yes |
| Impacts patient safety or clinical decision-making | — | Yes |
| Primarily focused on data accuracy and security without clinical decision-making | Yes | — |
| Classified as FDA Class I | Yes | Yes |
| Can be classified as FDA Class II or III | — | Yes |
| Requires premarket submission (510(k), De Novo, or PMA) | — | Yes |
| Generally exempt from premarket submission (low-risk) | Yes | — |
| Adheres to IEC 62304 software lifecycle and ISO 14971 risk management | — | Yes |
| Requires clinical validation or evidence of effectiveness | — | Yes |
| Compliant with HIPAA, GDPR, and applicable data protection regulations | Yes | Yes |
| Requires post-market surveillance for safety and performance | — | Yes |
How FDA Regulation of MDDS Has Evolved
The regulatory line between MDDS and SaMD wasn’t always where it is today. Understanding how the FDA classification of Medical Device Data Systems has evolved helps explain why some software that handles medical device data is regulated, and some isn’t.
Before 2011, MDDS were regulated as Class III medical devices—the highest-risk category —requiring premarket approval (PMA) before marketing. In 2011, the FDA reclassified MDDS to Class I with only general controls. Most MDDS became exempt from premarket submission requirements at that point, though they remained subject to FDA quality system regulations.
The 21st Century Cures Act (signed into law in December 2016) further changed the landscape. Section 3060 of the Cures Act amended the Federal Food, Drug, and Cosmetic Act to exclude certain software functions from the medical device definition entirely — including software that transfers, stores, converts formats, or displays clinical data, provided it does not analyze or interpret the data for clinical decision-making. In practice, this means a significant portion of what was previously regulated as MDDS is no longer regulated as a medical device at all.
What this means for software developers: the question “is my software MDDS?” now has three possible answers, not two. Software might be (a) outside FDA medical device regulation entirely under the 21st Century Cures Act exclusions, (b) regulated as MDDS (Class I, generally exempt from premarket submission), or (c) regulated as SaMD (Class I, II, or III, with corresponding premarket pathways). The differences matter — software outside FDA regulation has no FDA quality system burden, while regulated MDDS and SaMD do.
The line between the Cures Act–excluded software and regulated MDDS is sometimes unclear. The FDA’s policy for device software functions and mobile medical applications, updated periodically, provides specific examples of which software functions fall under each category. When in doubt, pre-submission consultation with the FDA is the practical way to resolve classification uncertainty before substantial development investment.
Key Takeaways
Understanding the differences between Medical Device Data Systems and Software as a Medical Device is essential for medical device companies navigating the evolving landscape of digital healthcare.
While MDDS plays a vital but passive role in managing and transferring medical data, SaMD actively engages in diagnosis, treatment, and monitoring, making it far more complex and higher risk. These distinctions influence not only their functionality but also their regulatory requirements and development processes.
By recognizing the unique challenges and opportunities of each software type, your company can better align its strategies to deliver innovative solutions that are both compliant and impactful. Whether focusing on data management or advancing clinical decision-making, clear differentiation and strategic planning are key to success in this dynamic industry.
Frequently Asked Questions About MDDS and SaMD
What is the difference between MDDS and SaMD?
MDDS (Medical Device Data Systems) are software that passively collect, store, transfer, or display medical device data without analyzing or interpreting it. SaMD (Software as a Medical Device) is software that actively performs medical functions — diagnosis, treatment, monitoring, or prediction — without being part of a hardware medical device. MDDS are typically Class I devices and are exempt from FDA premarket submission requirements. SaMD can be Class I, II, or III, with most products requiring a 510(k), De Novo, or PMA pathway.
Can the same software be both MDDS and SaMD?
A single software product can include both MDDS and SaMD functions, but the FDA classifies the software based on its highest-risk function. If any part of the software analyzes or interprets data for clinical decision-making, the entire product is typically classified as SaMD — even if other functions only handle data passively. Software developers planning a product that includes both passive data handling and active analysis should plan for SaMD-level regulatory burden across the entire codebase.
Does MDDS need FDA premarket approval?
Most MDDS do not need FDA premarket approval. Since 2011, MDDS have been classified as Class I medical devices and are typically exempt from premarket submission requirements (510(k), De Novo, or PMA). MDDS must still comply with general FDA quality system regulations, registration and listing requirements, and applicable data protection laws, such as HIPAA. The 21st Century Cures Act of 2016 further excluded certain device data system functions from FDA regulation entirely — meaning some software that would previously have been MDDS is no longer regulated as a medical device at all.
What FDA classification is MDDS?
MDDS are classified as Class I medical devices under FDA regulation. Class I represents the lowest risk category and is generally subject to the fewest regulatory requirements — most Class I devices, including MDDS, are exempt from premarket submission. The FDA’s MDDS classification regulation is found at 21 CFR 880.6310. Software that meets the MDDS definition but also analyzes or interprets data for clinical decisions is reclassified as SaMD and subject to higher-risk requirements.
Is MDDS regulated under IEC 62304?
MDDS are not strictly required to follow IEC 62304 in the same way SaMD is, because Class I MDDS are typically exempt from premarket submission. However, IEC 62304 is widely recognized as best practice for any medical device software lifecycle, and many MDDS developers voluntarily adopt it for quality and consistency reasons. SaMD developers, by contrast, are typically expected to follow IEC 62304 as part of FDA review — the standard defines the software lifecycle processes the FDA looks for in submissions.
What is the 21st Century Cures Act exclusion for medical software?
Section 3060 of the 21st Century Cures Act (2016) excluded certain software functions from the FDA’s definition of a medical device. These include software that transfers, stores, converts formats, or displays clinical data, provided the software does not analyze or interpret the data for clinical decision-making. The exclusion meaningfully reduced FDA regulation of pure data-handling software — software that would previously have been MDDS may now be entirely outside FDA medical device regulation. The line between Cures Act–excluded software and regulated MDDS depends on whether the software’s functions affect clinical decisions.
Not Sure Whether Your Software Is MDDS or SaMD?
The MDDS-vs-SaMD distinction sounds binary, but in practice it isn’t. Many software products straddle the line — handling data passively in some functions while analyzing or interpreting it in others. The 21st Century Cures Act adds a third possibility (software outside FDA medical device regulation entirely). Misclassification at the start of development typically costs months of rework — over-engineering low-risk software to SaMD standards, or under-documenting software that turns out to need premarket clearance.
Sequenex’s regulatory and software teams help medical device companies classify their software correctly before development starts — and then build to the regulatory pathway that applies, with Design History File documentation produced as engineering progresses, not retrofitted at submission.
